Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
19 July 2018 Photo Supplied
AEVGI advances Next-Generation Sequencing in Africa
Prof George Armah, Noguchi Memorial Institute for Medical Research, Ghana; Prof Carl Kirkwood, Bill and Melinda Gates Foundation, USA; Cornelius Hagenmeier, Director: Internationalisation, UFS; Prof Gert van Zyl, Dean: Health Sciences; Dr Martin Nyaga, Senior Lecturer in the NGS Unit; Prof Joyce Tsoka-Gwegweni, Vice-Dean: Health Sciences; Dr Glen Taylor, Senior Director: Research and Development; Prof Jeffrey Mphahlele, Vice-President, South African Medical Research Council.

The inaugural edition of the University of the Free State (UFS) Next-Generation Sequencing (NGS) Data and Bioinformatics Workshop, hosted by the UFS-NGS Unit in the UFS Faculty of Health Sciences, marked a new beginning for the advancement of NGS in Africa under the auspices of the African Enteric Viruses Genome Initiative (AEVGI), which was recently funded by the Bill and Melinda Gates Foundation.

The AEVGI will generate rotavirus genomes at the UFS-NGS Unit to investigate the long-term effects of the introduction of the monovalent RV1 vaccine in three African countries – Ghana, Malawi, and South Africa.

The workshop attracted over 90 participants from 15 national and international institutions, with organisations from seven different countries as well as company representatives attending the event. The workshop kicked off with a courtesy call to the Rector and Vice-Chancellor, Prof Francis Petersen, followed by a stakeholder meeting with the executive management of the UFS.

The funding was secured through an award to the principal investigator, Dr Martin Nyaga, and sub-awards to co-investigators, Dr Khuzwayo Jere, Dr Francis Dennis, and Dr Valentine Ndze. According to attendee evaluations of the workshop, the remarkable performance of the workshop instructors was outstanding. Through practical sessions, participants were equipped with knowledge on how to apply several tools of genetic data analysis, using the rotavirus genome as a model to construct and interpret different genomic datasets.

A total of 65 students attended the hands-on workshop, the majority of which were from South African higher-education institutions. The organisers are grateful to the sponsors, particularly to the Bill and Melinda Gates Foundation and the University of the Free State, for making the workshop a success. Whitehead Scientific and the South African Medical Research Council also played a major role in the success of the workshop. The local organising committee consisted of Dr Martin Nyaga (host, convener and chair), Dr Saheed Sabiu (secretary), and Mr Stephanus Riekert (principal ICT support).

News Archive

Researcher shares platform with Nobel Laureate at conference on nanomedicine
2013-01-10

Prof. Lodewyk Kock at the Everest viewpoint with Mount Everest behind him.
10 January 2013

Profs. Lodewyk Kock and Robert Bragg from the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS) both presented lectures at the first International Conference on Infectious Diseases and Nanomedicine that was held in Kathmandu, Nepal, late last year.

At the conference, also attended by senior representatives from the International Union of Microbiological Societies (IUMS), Prof. Kock delivered one of the two opening lectures, titled: Introducing New Nanotechnologies to Infectious Diseases (the other opening lecture was presented by Nobel Laureate, Prof. Barry J. Marshal). Prof. Kock also participated in the farewell address.

In two excellent lectures, Prof. Bragg spoke on Bacteriophages as potential treatment option of antibiotic-resistant bacteria, and on Bacterial resistance to quaternary ammonium compounds.

For Prof. Kock this very first conference on infectious diseases and nanomedicine was followed by a very exciting yeast research excursion through the Mount Everest Highway which winds through the villages of the Sherpa tribe.

He describes his journey: “The Mount Everest Highway is a rough road stretching through hills and glacial moraines of unfamiliar altitudes and cold temperatures. Throughout the journey I had to take care of not contracting altitude sickness which causes severe headaches and dizziness.

“The only way of transport is on foot, on long-haired cattle called Yaks, donkeys and by helicopter. After flying by plane from Kathmandu (the capital of Nepal), I landed at Lukla, regarded as the most dangerous airport in the world due to its short elevated runway and mountainous surroundings. From Lukla, the land of the Sherpa, I walked (trekked) with my Sherpa guide and porter (carrier) along the Everest Highway surrounded by various Buddhist Mani scripture stands, other Buddhist representations and many spectacular snow-tipped mountains of more than 6 000 m above sea level. Of these, the majestic mountain called Ama Dablam (6 812 m), the grand 8 516 m high peak of Lhotse and to its left the renowned Mount Everest at 8 848 m in height, caught my attention.

“Dwarfed by these mountain peaks on the horizon, I passed various villages until I eventually reached the beautiful village called Namche Bazar, the heart of the Khumbu region and hometown of the Sherpa. This took three days of up to six hours walking per day, while I spent the nights at the villages of Phakding and Monjo. From there I walked along the Dudh Kosi River which stretches towards Mount Everest, until I reached the high altitude Everest viewpoint – the end of my journey, after which I trekked back to Lukla to return to Kathmandu and South Africa.

“This expedition is the first exploration to determine the presence of yeasts in the Everest region. Results from this excursion will be used in collaborative projects with local universities in Nepal that are interested in yeast research.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept